StockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to “Buy”

Esperion Therapeutics (NASDAQ:ESPR) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Thursday.

Several other brokerages also recently commented on ESPR. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Wednesday, October 2nd. Needham & Company LLC cut their target price on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $8.17.

Esperion Therapeutics Price Performance

NASDAQ:ESPR opened at $2.21 on Thursday. The firm has a market capitalization of $433.66 million, a price-to-earnings ratio of -2.57 and a beta of 0.96. The business has a 50 day simple moving average of $1.90 and a 200-day simple moving average of $2.13. Esperion Therapeutics has a 1 year low of $0.87 and a 1 year high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Monday, August 12th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.10. The firm had revenue of $73.83 million for the quarter, compared to analysts’ expectations of $51.90 million. As a group, analysts expect that Esperion Therapeutics will post -0.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new stake in Esperion Therapeutics in the 1st quarter valued at about $69,000. CVI Holdings LLC purchased a new stake in shares of Esperion Therapeutics in the first quarter valued at approximately $37,000. Susquehanna Fundamental Investments LLC bought a new position in Esperion Therapeutics in the first quarter worth approximately $446,000. State Board of Administration of Florida Retirement System purchased a new position in Esperion Therapeutics during the 1st quarter worth $50,000. Finally, Tocqueville Asset Management L.P. bought a new stake in Esperion Therapeutics during the 1st quarter valued at $107,000. 47.39% of the stock is currently owned by institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.